U.S., Dec. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07264673) titled 'A Randomized Phase II Trial of Cemiplimab Plus OSE2101 ( TEDOPI(R)) as Maintenance Therapy in ctDNA Positive NSCL. The Cemited Study.' on Nov. 24.
Brief Summary: This is a phase II randomized study investigating whether a combination maintenance with Cemiplimab and OSE2101 (TEDOPI(R)) could increase ctDNA clearance rate versus standard maintenance therapy in HLA-A2 positive NSCLC patients not progressing after 4 cycles of chemo-immunotherapy.
Study Start Date: April 17
Study Type: INTERVENTIONAL
Condition:
NSCLC
Intervention:
DRUG: Tedopi
Cemiplimab + OSE2101 (TEDOPI(R)) (ARM B: experimental arm)
DRUG: Cemiplimab
Cemiplimab ...